Abstract
Radiotherapy of thoracic and chest wall tumors, if all or part of the heart was included in the radiation field, can lead to radiation-induced heart disease (RIHD), a late and potentially severe side effect. RIHD presents clinically several years after irradiation and manifestations include accelerated atherosclerosis, pericardial and myocardial fibrosis, conduction abnormalities, and injury to cardiac valves. The pathogenesis of RIHD is largely unknown, and a treatment is not available. Hence, ongoing pre-clinical studies aim to elucidate molecular and cellular mechanisms of RIHD. Here, an overview of recent pre-clinical studies is given, and based on the results of these studies, potential targets for intervention in RIHD are discussed.
Keywords: Radiation, heart, animal models, transforming growth factor-beta, renin-angiotensin system, mast cells, endothelin system, sensory nerves, models, transforming, angiotensin, endothelin, sensory, (RIHD), atherosclerosis, pericardial, myocardial fibrosis, pathogenesis, (myocardial necrosis, (PET), (SPECT), (RAS), Endothelial dysfunction, chemokines, TGF-β, mRNA, (Ang II), ACE, Captopril, (Ws), (CGRP), (TNF-α), IGF-1, (MMP), ETA, ETB
Current Drug Targets
Title: Potential Targets for Intervention in Radiation-Induced Heart Disease
Volume: 11 Issue: 11
Author(s): M. Boerma and M. Hauer-Jensen
Affiliation:
Keywords: Radiation, heart, animal models, transforming growth factor-beta, renin-angiotensin system, mast cells, endothelin system, sensory nerves, models, transforming, angiotensin, endothelin, sensory, (RIHD), atherosclerosis, pericardial, myocardial fibrosis, pathogenesis, (myocardial necrosis, (PET), (SPECT), (RAS), Endothelial dysfunction, chemokines, TGF-β, mRNA, (Ang II), ACE, Captopril, (Ws), (CGRP), (TNF-α), IGF-1, (MMP), ETA, ETB
Abstract: Radiotherapy of thoracic and chest wall tumors, if all or part of the heart was included in the radiation field, can lead to radiation-induced heart disease (RIHD), a late and potentially severe side effect. RIHD presents clinically several years after irradiation and manifestations include accelerated atherosclerosis, pericardial and myocardial fibrosis, conduction abnormalities, and injury to cardiac valves. The pathogenesis of RIHD is largely unknown, and a treatment is not available. Hence, ongoing pre-clinical studies aim to elucidate molecular and cellular mechanisms of RIHD. Here, an overview of recent pre-clinical studies is given, and based on the results of these studies, potential targets for intervention in RIHD are discussed.
Export Options
About this article
Cite this article as:
Boerma M. and Hauer-Jensen M., Potential Targets for Intervention in Radiation-Induced Heart Disease, Current Drug Targets 2010; 11 (11) . https://dx.doi.org/10.2174/1389450111009011405
DOI https://dx.doi.org/10.2174/1389450111009011405 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Cardiovascular and Hematological Agents (Executive Editor: Johann Auer)]
Current Pharmaceutical Design Nutritional and therapeutic approaches to modulate NADPH oxidase-derived ROS signaling in platelets.
Current Pharmaceutical Design The Effect of Ethyl Acetate Extract of Pomelo Mix on Systemic Exposure of Verapamil in Rabbits
Drug Metabolism Letters The Role of Adipocytokines and Neurohormonal Dysregulation in Metabolic Syndrome
Current Diabetes Reviews A1 Adenosine Receptor Agonists: Medicinal Chemistry and Therapeutic Potential
Current Pharmaceutical Design Molecule of the Month
Current Topics in Medicinal Chemistry Smoking and Congenital Heart Disease: The Epidemiological and Biological Link
Current Pharmaceutical Design The Role of Beta-Blocker in Heart Failure in Adults with Congenital Heart Disease
Reviews on Recent Clinical Trials The Proteomic Approach in the Development of Prognostic Biomarkers in Atherothrombosis
Recent Patents on Cardiovascular Drug Discovery Use of Bipolar Radiofrequency Catheter Ablation in the Treatment of Cardiac Arrhythmias
Current Cardiology Reviews Omega-3 and Renal Function in Older Adults
Current Pharmaceutical Design Renal Function, Albumin-Creatinine Ratio and Pulse Wave Velocity Predict Silent Coronary Artery Disease and Renal Outcome in Type 2 Diabetic and Prediabetic Subjects
Current Hypertension Reviews Fatty Acid Intakes and Coronary Heart Disease Mortality in Japan: NIPPON DATA90, 1990-2005
Current Nutrition & Food Science New Treatments for COPD in the Elderly
Current Pharmaceutical Design Editorial (Thematic Issue: Cardiovascular Drug Therapy in Paediatric Age: From Metabolomics to Clinical Practice)
Current Medicinal Chemistry Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice
Current Pharmaceutical Design Pregnancy, Programming and Preeclampsia: Gap Junctions at the Nexus of Pregnancy-induced Adaptation of Endothelial Function and Endothelial Adaptive Failure in PE
Current Vascular Pharmacology Cigarette Smoking and Hypertension
Current Pharmaceutical Design The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism Oxidative Stress and Mitochondrial Impairment After Treatment with Anti-HIV Drugs: Clinical Implications
Current Pharmaceutical Design